David M. Holtzman, MD

Dr. David M. Holtzman is a world-renowned physician-scientist and is currently a Professor of Neurology, scientific director of the Hope Center for Neurological Disorders, and Associate Director of the Knight ADRC at Washington University in St. Louis. Dr. Holtzman received his BS and MD degrees from Northwestern University, followed by a Neurology residency and postdoctoral training at UCSF. Over the last 27 years, Dr. Holtzman's laboratory has focused on studying the molecular mechanisms underlying neurodegeneration and Alzheimer's disease, particularly the neurobiology of ApoE and its receptors, ApoE and TREM2 effects on the innate immune system, and how ApoE, Aß binding molecules, and other factors such as neuronal activity and sleep influence Aß and tau metabolism and Alzheimer's disease progression. Dr. Holtzman's laboratory has developed an anti-Aß antibody currently in phase III secondary prevention trial for AD (A4) and an anti-ApoE antibody being developed for human trials as well as several laboratory techniques such as microdialysis method and metabolic labeling techniques allowing to measure the rates of protein synthesis and clearance in the CNS. Dr. Holtzman has received multiple honors, several of his accomplishments include being a recipient of the Potamkin prize and MetLife award for research on Alzheimer's disease, Rainwater Prize for outstanding innovation in neurodegenerative disease research, election to the National Academy of Medicine, election to the National Academy of Inventors, being appointed to the National Advisory council of the NINDS and NIA, the Chancellor's Award for innovation and entrepreneurship and the Carl and Gerty Cori award from Washington University, elected Fellow of the AAAS, and being past president of the American Neurological Association. In addition, Dr. Holtzman has trained and mentored over 70 graduate students, postdoctoral fellows, and physician-scientists, many of whom are in successful careers in academia and industry.